[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uncontrolled-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uncontrolled-asthma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100648316","impact-of-gdmt-in-uncontrolled-asthma-patients-receiving-mhd-inhaled-corticosteroids--long-acting-2-agonist-100648316",false,"NCT07718724","Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist","A Prospective, Multicenter, Cluster-Randomized Trial to Evaluate the Impact of Guideline-Directed Medical Therapy in Uncontrolled Asthma Patients Receiving Medium-to-High Dose Inhaled Corticosteroids Plus Long-acting β2 Agonist","PRECISION","Inclusion Criteria:\n\n1. Sign the informed consent form before any study-related procedures;\n2. Age 18-75 years (inclusive) at Visit 0;\n3. Have a written diagnosis of asthma for more than 6 months prior to Visit 0, and have evidence of reversible airflow limitation prior to Visit 0. Evidence of reversible airflow limitation includes: post-bronchodilator increase in Forced Expiratory Volume in 1 second (FEV1) of ≥12% and an absolute increase of ≥200 mL, or average daily diurnal Peak Expiratory Flow (PEF) variability \\>10%, or an increase in FEV1 of ≥12% and an absolute increase of ≥200 mL compared to baseline after 4 weeks of treatment containing ICS, or a positive bronchial provocation test record. If no prior record exists, reversible airflow limitation must be confirmed and documented via a bronchodilator test during Visit 0;\n4. Under the usage of MD\u002FHD ICS-LABA;\n5. Experienced one or more exacerbations within the past year;\n\nExacerbation is defined as meeting any of the following criteria:\n\n1. Use of systemic corticosteroids (or a temporary increase in the stable dose of baseline oral corticosteroids) for at least 3 days; a single injection of a depot long-acting corticosteroid can be considered equivalent to a 3-day course of systemic corticosteroids;\n2. An emergency department or urgent care site visit for asthma (defined as being evaluated and treated in the emergency department or urgent care site for \\\u003C 24 hours) requiring the use of systemic corticosteroids for at least 3 days (as described above);\n3. Hospitalization for asthma (defined as admission to a hospital and\u002For being evaluated and treated in a healthcare facility for ≥ 24 hours).\n\nExclusion Criteria:\n\n1. Previous written diagnosis as \"Severe Asthma\"; Diagnosis of Severe Asthma includes: severe asthma, or related diagnoses containing \"severe asthma\", or \"bronchial asthma (severe)\".\n2. Imaging suggests the presence of bullae or cystic bronchiectasis;\n3. Currently participating in other interventional studies;\n4. Previous use of biologics for asthma treatment;\n5. Using systemic glucocorticoids for other diseases;\n6. History of respiratory tract infection within 4 weeks prior to Visit 0 (upper respiratory tract infections and lower respiratory tract infections);\n7. Any significant disease or disorder (e.g., cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine\u002Fmetabolic, malignant, psychiatric, or significant physical impairment, etc.) which, in the opinion of the investigator, may put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to comply with GDMT.","ALL",{"count":19,"type":20},540,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA.\n\n* The intervention period will be up to 48 weeks;\n* The frequency of follow-up is every 12 weeks.",[26],"Uncontrolled Asthma",[15],"NOT_YET_RECRUITING","2026-07-16",{"date":31,"type":32},"2026-07-22","ACTUAL",{"date":34,"type":20},"2026-08-15",{"date":36,"type":20},"2028-04-30",{"name":38,"class":39},"AstraZeneca","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100556141","clinical-demographic-profiles-of-patients-with-uncontrolled-asthma-in-russia-multi-center-observational-registry-study-100556141","NCT06521229","Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study","An Ambispective Observational Multicenter Registry of Patients With Uncontrolled Asthma in the Population of the Russian Federation","ICEBERG","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of inclusion;\n2. Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;\n3. Patients with diagnosis of uncontrolled mild and moderate asthma (according to Global Initiative for Asthma (GINA) score);\n4. Patients with the availability of at least 52 weeks of follow-up data (prior to inclusion) in the medical records.\n\nExclusion Criteria:\n\n1. Patients with severe asthma or\u002Fand patients receiving any biological therapy currently or within 52 weeks prior to inclusion;\n2. Presence of chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (ILF) currently or in the anamnesis;\n3. The participation in any clinical study currently or within 52 weeks prior to inclusion;\n4. An acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results.",{"count":50,"type":20},9000,"OBSERVATIONAL","This study is a multi-centre, non-interventional, observational, ambispective registry. Planned study population consists of 9 000 adult patients with uncontrolled asthma receiving treatment according to standard of care (except biologics). Planned number of study site is 70 outpatient centers with experience of uncontrolled asthma treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled asthma in different regions in the most comprehensive way).",[26],[55],"uncontrolled asthma","RECRUITING","2026-04-17",{"date":59,"type":32},"2026-04-20",{"date":61,"type":32},"2024-06-27",{"date":63,"type":20},"2026-09-30",{"name":38,"class":39},47,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100573971","telemedicine-education-for-caregivers-and-asthma-control-in-children-100573971","NCT06753214","Telemedicine Education for Caregivers and Asthma Control in Children","Effectiveness of Telemedicine-Based Education for Caregivers on Asthma Control in Children With Uncontrolled Asthma: A Randomized Controlled Trial","TCARE","Inclusion Criteria:\n\n* Pediatric asthma patients diagnosed according to the GINA guidelines, classified as having uncontrolled asthma, are managed and followed up for at least 1 month at the pediatric asthma unit of the outpatient department.\n\nExclusion Criteria:\n\n* Pediatric patients who do not cooperate or are unable to complete the Childhood Asthma Control Test questionnaire.\n* Caregivers who cannot complete the questionnaires related to the assessment of asthma control and associated factors.\n* Pediatric patients who have siblings participating in the study.\n* Patients currently participating in another clinical study (excluding non-interventional studies or registries).\n* Failure to return for a second visit within 6 months following enrollment.","4 Years","16 Years",{"count":77,"type":20},64,[23],"Asthma control in pediatric patients remains a critical issue for healthcare providers. Telemedicine has emerged as an effective solution for overcoming distance barriers in healthcare delivery. This study aims to utilize telemedicine-based education for caregivers to improve asthma control in children with uncontrolled asthma. By providing remote guidance and support, the study seeks to enhance caregivers' knowledge and management practices, ultimately leading to better asthma outcomes for pediatric patients.",[26,81],"Telemedicine-Based Education",[83,84,85,86],"Asthma","Pediatrics","Telemedicine","Uncontrolled asthma","2025-07-02",{"date":89,"type":32},"2025-07-08",{"date":91,"type":32},"2024-06-05",{"date":93,"type":20},"2026-06",{"name":95,"class":96},"Can Tho University of Medicine and Pharmacy","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100568462","exploring-the-lived-experience-of-young-adults-with-severe-asthma-100568462","NCT06681545","Exploring the Lived Experience of Young Adults With Severe Asthma","An Exploration of the Experiences and Support Needs of Young Adults With Severe and Uncontrolled Asthma","EaSY","Inclusion Criteria:\n\n* A confirmed diagnosis of severe or uncontrolled asthma under the care of the Manchester or Liverpool severe asthma services\n* Participants aged 16-25 years.\n* Informed consent provided.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Participants with additional long-term conditions who identify their dominant health concern to be non-asthma related.\n* Focus group only- inability to converse in English","25 Years",{"count":107,"type":20},46,"Asthma is a serious long-term lung condition caused by swollen airways that narrow. This causes wheezing, chest tightness, and breathlessness. Most asthma is well-controlled with medication.\n\nHowever, 5-10% of asthmatics have severe asthma where treatment does not control symptoms and up to 67% of asthmatics have uncontrolled asthma, caused by not always taking medication as recommended, lifestyle choices or other health problems worsening their asthma.\n\nIn the UK, asthma affects around 800,000 young adults. This group is at high-risk of having poor asthma control, worse outcomes than other age-groups. This is because young adults need care that differs from other age-groups and current care is not meeting these needs.\n\nThere is little information on the experiences and needs of this group and very few studies exist, exploring how to improve care. This study will explore the experiences and needs of young adults (age16-25) with severe and uncontrolled asthma.\n\nMethods. The investigators will perform two study-arms with young adults with severe\u002Funcontrolled asthma in Manchester and Liverpool severe asthma centres:\n\nStudy-arm 1: Interview participants using photographs chosen by them to help explain their experiences of living with asthma and support that they need.\n\nStudy arm 2: Perform group interviews to understand participants' thoughts around the insights from study-arm 1 combined with their own experiences. To explore and develop ideas on how to improve future care.\n\nAt the end of both study arms, a workshop involving patients and stakeholders involved in delivering care will take place, to identify a joint goal of how to improve care in this cohort and map ways in which to achieve this.\n\nTogether, the study results and workshop will increase our understanding of the experiences and needs of young adults with asthma. Helping us to identify new ways to improve care which can be tested in future research.",[83,110,26],"Severe Asthma",[112,113,114],"young people","young adults","young person","2025-02-03",{"date":117,"type":32},"2025-02-05",{"date":119,"type":32},"2024-11-25",{"date":121,"type":20},"2025-10-31",{"name":123,"class":124},"Manchester University NHS Foundation Trust","OTHER_GOV"]